Amgen announced landmark trial results showing its cholesterol-lowering drug Repatha significantly reduces heart disease deaths, heart attacks, and strokes in a primary prevention population. This broadens the drug’s potential market beyond high-risk patients, supporting increased adoption of PCSK9 inhibitors and contributing to a recent rise in Repatha’s sales.